Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid an­ti­body

At the two-year mark, Roche’s Evrys­di (ris­diplam) ei­ther main­tained or im­proved mo­tor func­tion from a one-year check-up in pa­tients aged 2 to 25 with Types …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.